Synthetic Biologics has partnered with Intrexon for a second time to develop and commercialise monoclonal antibodies for three undisclosed infectious disease indications utilising Intrexon's synthetic biology technologies. In return, Intrexon will receive 3.6 million shares of Synthetic common stock, bringing its ownership position in the company to approximately 18%. Intrexon also stands to gain milestone payments and royalties and the collaboration may be expanded to include up to five additional infectious disease indications.